Ion Alexie, MD
Infectious Disease · Las Vegas, NVNPI 1881621662
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Melinta Therapeutics, LLC at 45.8% of the total. Reporting peaked in 2019 at $148 and has fallen 79.1% since, to $31 in 2023. That places this record below the midpoint for infectious disease clinicians in NV, where the typical reported total is $1,077.
Across 13 payments — averaging $28.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Melinta Therapeutics, LLC$168
- Merck$92
- Viiv Healthcare Company$43
- Boston Scientific$32
- Gilead$31
What the payments were for
- Food & beverage$366100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Melinta Therapeutics, LLC | 7 | $168 |
| Merck | 1 | $92 |
| Viiv Healthcare Company | 2 | $43 |
| Boston Scientific | 2 | $32 |
| Gilead | 1 | $31 |
How this compares
$366 in reported general payments places this provider in the 25th percentile of 65 infectious disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 26 | $79,397 |
| Meropenem | 15 | $2,765 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Las Vegas
- Alireza FarabiLas Vegas$588K
- Dhiresh JoshiLas Vegas$96K
- Shaker ItaniLas Vegas$52K
- Dhaval ShahLas Vegas$27K
- Alka RebentishLas Vegas$23K
- Ronald ShockleyLas Vegas$13K
- Chukwudum UcheLas Vegas$13K
- John OreillyLas Vegas$8K
- Li-Chien ChenLas Vegas$8K
- Naima ZaheerLas Vegas$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.